Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global eye health company, has been navigating a complex market landscape characterized by both promising opportunities and significant challenges.

Bausch + Lomb (NYSE:BLCO – Get Free Report) had its price objective lowered by stock analysts at Royal Bank of Canada from ...

When he was twenty years old in 1849, he emigrated to the United States. Lomb worked as a carpenter before he joined John Jacob Bausch, the owner of a retail optical shop in Rochester. Lomb invested ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...